The FDA raised concerns about possible stroke and bone-related safety risks tied to Johnson & Johnson's proposed diabetes treatment canagliflozin, or Invokana. An analysis of cardiovascular events showed a numerical imbalance in strokes although it didn't show a greater risk in a combined measure of cardiovascular deaths, hospitalization, strokes and heart attacks, the FDA said. The drug will be reviewed by the FDA's endocrinologic and metabolic drugs advisory committee as part of the approval process.

Full Story:
Fox Business

Related Summaries